These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 8700557)

  • 1. Transformational and altered signal transduction by a naturally occurring mutant EGF receptor.
    Moscatello DK; Montgomery RB; Sundareshan P; McDanel H; Wong MY; Wong AJ
    Oncogene; 1996 Jul; 13(1):85-96. PubMed ID: 8700557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-Shc: a neural-specific adapter molecule that mediates signaling from neurotrophin/Trk to Ras/MAPK pathway.
    Nakamura T; Sanokawa R; Sasaki Y; Ayusawa D; Oishi M; Mori N
    Oncogene; 1996 Sep; 13(6):1111-21. PubMed ID: 8808684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer.
    Tang CK; Gong XQ; Moscatello DK; Wong AJ; Lippman ME
    Cancer Res; 2000 Jun; 60(11):3081-7. PubMed ID: 10850460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epidermal growth factor ligand-independent, unregulated, cell-transforming potential of a naturally occurring human mutant EGFRvIII gene.
    Batra SK; Castelino-Prabhu S; Wikstrand CJ; Zhu X; Humphrey PA; Friedman HS; Bigner DD
    Cell Growth Differ; 1995 Oct; 6(10):1251-9. PubMed ID: 8845302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Grb2 regulation of the actin-based cytoskeleton is required for ligand-independent EGF receptor-mediated oncogenesis.
    Boerner JL; Danielsen AJ; Lovejoy CA; Wang Z; Juneja SC; Faupel-Badger JM; Darce JR; Maihle NJ
    Oncogene; 2003 Oct; 22(43):6679-89. PubMed ID: 14555981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rit, a non-lipid-modified Ras-related protein, transforms NIH3T3 cells without activating the ERK, JNK, p38 MAPK or PI3K/Akt pathways.
    Rusyn EV; Reynolds ER; Shao H; Grana TM; Chan TO; Andres DA; Cox AD
    Oncogene; 2000 Sep; 19(41):4685-94. PubMed ID: 11032018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of signal specific receptor tyrosine kinase oncoproteins reveals that pathways downstream from Grb2 or Shc are sufficient for cell transformation and metastasis.
    Saucier C; Papavasiliou V; Palazzo A; Naujokas MA; Kremer R; Park M
    Oncogene; 2002 Mar; 21(12):1800-11. PubMed ID: 11896612
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Unique role of SNT-2/FRS2beta/FRS3 docking/adaptor protein for negative regulation in EGF receptor tyrosine kinase signaling pathways.
    Huang L; Watanabe M; Chikamori M; Kido Y; Yamamoto T; Shibuya M; Gotoh N; Tsuchida N
    Oncogene; 2006 Oct; 25(49):6457-66. PubMed ID: 16702953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of EGFR-mediated phosphoinositide-3-OH kinase (PI3-K) signaling and glioblastoma phenotype by signal-regulatory proteins (SIRPs).
    Wu CJ; Chen Z; Ullrich A; Greene MI; O'Rourke DM
    Oncogene; 2000 Aug; 19(35):3999-4010. PubMed ID: 10962556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of tyrosine kinases by alpha1A-adrenergic and growth factor receptors in transfected PC12 cells.
    Zhong H; Minneman KP
    Biochem J; 1999 Dec; 344 Pt 3(Pt 3):889-94. PubMed ID: 10585878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stimulation of mitogenic pathways through kinase-impaired mutants of the epidermal growth factor receptor.
    Ewald JA; Coker KJ; Price JO; Staros JV; Guyer CA
    Exp Cell Res; 2001 Aug; 268(2):262-73. PubMed ID: 11478852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of the EGF receptor by insertional mutations in its juxtamembrane regions.
    Sorokin A
    Oncogene; 1995 Oct; 11(8):1531-40. PubMed ID: 7478577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Grb2 regulates Stat3 activation negatively in epidermal growth factor signalling.
    Zhang T; Ma J; Cao X
    Biochem J; 2003 Dec; 376(Pt 2):457-64. PubMed ID: 14498832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ras effector pathway activation by epidermal growth factor is inhibited in vivo by exoenzyme S ADP-ribosylation of Ras.
    Henriksson ML; Rosqvist R; Telepnev M; Wolf-Watz H; Hallberg B
    Biochem J; 2000 Apr; 347 Pt 1(Pt 1):217-22. PubMed ID: 10727422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. c-Myc is required for transformation of FDC-P1 cells by EGFRvIII.
    Rath O; Himmler A; Baum A; Sommergruber W; Beug H; Metz T
    FEBS Lett; 2007 May; 581(13):2549-56. PubMed ID: 17499721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth inhibition of breast cancer cells by Grb2 downregulation is correlated with inactivation of mitogen-activated protein kinase in EGFR, but not in ErbB2, cells.
    Tari AM; Hung MC; Li K; Lopez-Berestein G
    Oncogene; 1999 Feb; 18(6):1325-32. PubMed ID: 10022814
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new function for phospholipase C-gamma1: coupling to the adaptor protein GRB2.
    Pei Z; Maloney JA; Yang L; Williamson JR
    Arch Biochem Biophys; 1997 Sep; 345(1):103-10. PubMed ID: 9281317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ornithine decarboxylase transformation of NIH/3T3 cells is mediated by altered epidermal growth factor receptor activity.
    Moshier JA; Malecka-Panas E; Geng H; Dosescu J; Tureaud J; Skunca M; Majumdar AP
    Cancer Res; 1995 Nov; 55(22):5358-65. PubMed ID: 7585601
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Inhibition of ras-dependent transformation by using dominant negative ras mutant N116Y].
    Yokoyama T
    Hokkaido Igaku Zasshi; 1995 May; 70(3):459-71. PubMed ID: 7590597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutation at tyrosine residue 1337 abrogates ligand-dependent transforming capacity of the FLT4 receptor.
    Fournier E; Dubreuil P; Birnbaum D; Borg JP
    Oncogene; 1995 Sep; 11(5):921-31. PubMed ID: 7675451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.